Trial
NCT00597909
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Hepatic Encephalopathy
Intervention
sodium phenylacetate and sodium benzoate injection 10% / 10%
Why stopped
Study was terminated due to lack of enrollment and business decisions.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-17